10 Apr 2013 --- With organic growth of 9% in the first half of the financial year 2012/13, Chr. Hansen delivered a strong interim result, with organic revenue growth of 9% (excluding carmine price effect) in the first half of 2012/13. Preliminary analysis of two clinical studies relating to gastrointestinal health has been finalized.
